Home > Expanded Access > Expanded Access to Provide Loxo-195 for the Treatment of Cancers With a NTRK Gene Fusion

Bayer

Expanded Access to Provide Loxo-195 for the Treatment of Cancers With a NTRK Gene Fusion

Official Title: 
Expanded Access to Provide LOXO-195 for the Treatment of Cancers With a NTRK Gene Fusion
Brief Summary: 
Loxo-195 expanded access is for minor and adult patients with cancer having a change in a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligible for an ongoing Loxo-195 clinical trial or have other considerations that prevent access to Loxo-195 through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion, including blood cancers, who have previously received tropomyosin receptor kinase (TRK) inhibitor therapy.
Available
EA Type
Individual Patients
Solid Tumors Harboring NTRK Fusion

Drug: BAY2731954
BAY2731954 is administered as capsules or liquid formulation.
Other Name: Loxo-195

Eligibility Criteria: 

Inclusion Criteria:

- Diagnosis of cancer with a NTRK1, NTRK2, and NTRK3 gene fusion

- Previous treatment with a kinase inhibitor with known activity on TRK inhibition

- Unable to participate in an ongoing Loxo-195 clinical trial

- Medically suitable for treatment with Loxo-195

Exclusion Criteria:

- Currently enrolled in an ongoing clinical study with a TRK inhibitor

Eligibility Gender: 
All
Eligibility Age: 
Minimum: 1 Month
Contacts: 

Bayer Clinical Trials Contact
(+)1-888-84 22937
clinical-trials-contact@bayer.com

EA Number: 
Keywords: 
Metastatic cancer, Advanced cancer, Neurotrophic tyrosine receptor kinase (NTRK), NTRK1, NTRK2, NTRK3, Fusion Positive, Children
MeSH Terms: 
9-Fluoro-15-methyl-2,11,16,20,21,24-hexaazapentacyclo(16.5.2.02,6.07,12.021,25)pentacosa-1(24),7,9,11,18(25),19,22-heptaen-17-one
Disclaimer:
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.